Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

SAN DIEGO — Illumina, Inc. (NASDAQ: ILMN), renowned for its advancements in DNA sequencing and array-based technologies, today declared significant changes to its executive management team. Joydeep Goswami, who has notably contributed to the company’s strategic direction, will transition to an advisory role through June 30, supporting the introduction of two key appointments within the company.

Ankur Dhingra will take on the role of Chief Financial Officer beginning April 15, bringing extensive experience from the life sciences tools, diagnostics, and pharmaceutical industries. Dhingra’s previous positions include CFO of Summit Therapeutics Inc. and CAREDx, Inc., alongside an 18-year tenure at Agilent Technologies where he was VP of Investor Relations and held several finance leadership roles. His expertise spans growth and margin improvement strategies, P&L commitments, and leading global finance teams.

Jakob Wedel has been appointed as Chief Strategy and Corporate Development Officer, also effective April 15. Previously Illumina’s CEO Chief of Staff, where he led strategic transformation initiatives, Wedel’s career includes senior strategy roles at EY, McKinsey & Company, and Bain & Company. His early entrepreneurial venture includes co-founding the Nordic strategy firm QVARTZ, which Bain later acquired.

“I am proud of the talent joining our management team as we work to deliver on Illumina’s mission to improve human health by unlocking the power of the genome,” stated Jacob Thaysen, Illumina CEO. “Ankur brings deep financial expertise, investor and leadership experience, and industry knowledge to Illumina’s CFO role, and Jakob has keen insights gained from 25 years in strategy leadership roles with global consulting firms. Both are deeply committed to serving our customers and helping Illumina grow.”

Both Dhingra and Wedel are relocating to San Diego to assume their new roles, succeeding Goswami who has filled these positions since early 2023. Goswami, having joined Illumina in 2019 to lead strategy and corporate development, will continue as an advisor from April 15 to June 30, ensuring a smooth transition.

“We are grateful to Joydeep for his many contributions to Illumina over more than four years, and for most recently leading these two key functions,” added Thaysen. “Joydeep will continue with us for several weeks to support a smooth leadership transition.”

Illumina has also reaffirmed its financial guidance for the first quarter and full year of 2024, reflecting the company’s steady trajectory and strategic foresight.

About Illumina:

Illumina is a global leader dedicated to improving human health by unlocking the power of the genome. The company’s innovative DNA sequencing and array-based technologies serve a wide array of customers in research, clinical, and applied markets. Its products support diverse applications across life sciences, oncology, reproductive health, agriculture, and other emerging areas, maintaining Illumina at the forefront of genetic research and clinical diagnostics.

SEO Friendly Meta Description:

You may like to read : 2024 Vision: Transforming Workplace Wellness with AI, Diversity, and Holistic Health Initiatives